GENE ONLINE|News &
Opinion
Blog

2021-08-17| ChinaCOVID-19

​​Does Sinovac’s CoronaVac Increase the Risk of Bell’s Palsy After Immunization?

by Joy Lin
Share To

First-time recipients of Sinovac’s COVID-19 vaccine (CoronaVac) face an increased risk of developing Bell’s palsy, a sudden and temporary facial paralysis, according to a study published in The Lancet Infectious Diseases journal.

The authors of the study advise that the protective effects of the vaccine far outweigh the risks. 

 

Association Between COVID-19 Vaccines and Bell’s Palsy

 

Cases of Bell’s palsy have been reported at higher rates in the clinical trials of Moderna’s and Pfizer/BioNTech’s mRNA vaccines, compared to what is expected in the general population. The rate of the adverse event occurring after immunization with inactivated COVID-19 vaccines, such as the Sinovac-developed CoronaVac, has not been published until a few days ago.

A recent study conducted in Hong Kong compared the rates of the adverse event within 42 days after immunization with either CoronaVac or Pfizer-BioNTech’s vaccine.

Of over 451,000 individuals who received the first shot of CoronaVac, 28 developed Bell’s palsy, compared to 16 out of over 537,000 individuals who received Pfizer’s shot.  Further analysis showed that nearly five more people out of 100,000 would develop the condition after the CoronaVac shot compared to natural occurrence in the general population. These results suggested a significantly higher risk of developing Bell’s palsy after CoronaVac vaccination, but not for Pfizer-BioNTech’s vaccine.

 

Vaccination Benefits Still Outweigh Risk

 

Bell’s palsy, also known as acute peripheral facial nerve palsy of unknown cause, is a sudden onset of facial paralysis that usually affects one side of the face or head. The effects are often temporary — with the right corticosteroid treatment, the vast majority (over 90%) of patients make a full recovery after 9 months.

“The beneficial and protective effects of the inactivated COVID-19 vaccines far outweigh the risk of this generally self-limiting adverse event,” the authors of the study affirmed, echoing the stance of many in the field.

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
R&D
Breakthrough Screening Platform to Assess SARS-CoV-2 Mutations and Potential Treatments
2024-04-16
GeneOnline’s Weekly News Highlights: Sept 17-Sept 22
2023-09-26
GeneOnline’s Weekly News Highlights: Sept 11-Sept 15
2023-09-19
LATEST
UC Riverside Scientists Unveil RNA-based Vaccine Strategy, Potentially Avoiding Endless Booster Shots
2024-05-02
Lilly’s Q1 2024 Financial Report: Full-Year Revenue Outlook Raised by $2 Billion, with a 67% Net Income Increase
2024-05-02
Taiwan Breakthrough: Next-Generation Sequencing Now Covered in Health Insurance, Benefitting 20,000 Cancer Patients Annually
2024-05-02
CellTech Accelerator and Cyto-Facto Inc. Forge Strategic Partnership to Advance CGT Industry Growth
2024-04-29
Kaiser’s Data Breach: 13.4 Million Affected in Healthcare Conglomerates Privacy Crisis
2024-04-26
Mechanisms of Allograft Rejection: Insights from Behind the Scenes
2024-04-25
ImmunityBio’s ANKTIVA® Granted FDA Approval: Breakthrough IL-15 Receptor Agonist First-in-Class for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
2024-04-24
EVENT
Scroll to Top